R/data.R
mstate_nma_surv.Rd
Curves of progression-free survival (PFS) and overall survival (OS) estimated using a Bayesian multi-state network meta-analyis (NMA). PFS is the duration of time a patient is alive without disease progression and OS is the duration of a time a patient is alive.
mstate_nma_pfs mstate_nma_os
A data.table with the following columns:
Line of treatment. Either first or second.
At 2nd line, equal to 1 if there is a T790M mutation and 0 otherwise.
The statistical model.
Name of the treatment.
Trial month.
Mean PFS/OS from the posterior distribution.
Median PFS/OS from the posterior distribution.
Lower limit of 95 percent credible interval from posterior distribution.
Upper limit of the 95 percent credible interval from the posterior distribution.
head(mstate_nma_pfs)#> line mutation model tx_name month mean median l95 #> 1: 1 NA Weibull erlotinib 0 1.0000000 1.0000000 1.0000000 #> 2: 1 NA Weibull erlotinib 1 0.9813128 0.9831876 0.9591186 #> 3: 1 NA Weibull erlotinib 2 0.9584437 0.9612476 0.9197846 #> 4: 1 NA Weibull erlotinib 3 0.9325516 0.9361429 0.8820475 #> 5: 1 NA Weibull erlotinib 4 0.9043601 0.9075891 0.8382485 #> 6: 1 NA Weibull erlotinib 5 0.8744189 0.8774188 0.7935833 #> u95 #> 1: 1.0000000 #> 2: 0.9931107 #> 3: 0.9808260 #> 4: 0.9653296 #> 5: 0.9478870 #> 6: 0.9284482head(mstate_nma_os)#> line mutation model tx_name month mean median l95 #> 1: 1 NA Weibull erlotinib 0 1.0000000 1.0000000 1.0000000 #> 2: 1 NA Weibull erlotinib 1 0.9990851 0.9993163 0.9969418 #> 3: 1 NA Weibull erlotinib 2 0.9971186 0.9975396 0.9926917 #> 4: 1 NA Weibull erlotinib 3 0.9940580 0.9946105 0.9867761 #> 5: 1 NA Weibull erlotinib 4 0.9898799 0.9905707 0.9786638 #> 6: 1 NA Weibull erlotinib 5 0.9845798 0.9853897 0.9697365 #> u95 #> 1: 1.0000000 #> 2: 0.9998248 #> 3: 0.9992038 #> 4: 0.9980502 #> 5: 0.9962049 #> 6: 0.9936172